Gefitinib (IRESSA) as a second-line treatment for advanced non-small cell lung cancer patients who failed first-line chemotherapy in Korea.

被引：0
|
作者：
Park, BB
Park, JO
Kim, SW
Kim, JH
Shin, SW
Ahn, MJ
Choi, JH
Lee, JS
Park, K
机构：
[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med,Div Oncol, Seoul, South Korea
[3] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul 120749, South Korea
[4] Korea Univ, Med Ctr, Anam Hosp, Dept Internal Med,Div Hematol Oncol, Seoul 136701, South Korea
[5] Hanyang Univ, Dept Internal Med, Hematol Oncol Sect, Seoul 133791, South Korea
[6] Ajou Univ, Dept Hematol Oncol, Sch Med, Suwon 441749, South Korea
[7] Gyeongsang Natl Univ, Coll Med, Dept Internal Med, Jinju, South Korea
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9056S / 9056S
页数：1
相关论文
共 50 条
  • [1] Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
    Wu, Jenn-Yu
    Yu, Chong-Jen
    Shih, Jin-Yuan
    Yang, Chih-Hsin
    Yang, Pan-Chyr
    LUNG CANCER, 2010, 67 (03) : 348 - 354
  • [2] Gefitinib(Iressa) as first-line therapy in advanced non-small lung cancer
    Zimmermann, M
    Luthi, F
    Zouhair, A
    Bauer, J
    Leyvraz, S
    Stupp, R
    LUNG CANCER, 2005, 49 : S276 - S276
  • [3] Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer
    Cao, Wa
    Li, Ai-Wu
    Ren, Sheng-Xiang
    Chen, Xiao-Xia
    Li, Wei
    Gao, Guang-Hui
    He, Ya-Yi
    Zhou, Cai-Cun
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (16) : 6799 - 6804
  • [4] Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer
    Cucevic, B
    Samarzija, M
    Baricevic, D
    Jakopovic, M
    Redzepi, G
    Samija, M
    COLLEGIUM ANTROPOLOGICUM, 2005, 29 (02) : 583 - 588
  • [5] BIOMARKERS OF TORCH TRIAL ON FIRST-LINE ERLOTINIB FOLLOWED BY SECOND-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
    Tsao, M. S.
    Gallo, C.
    Saieg, M.
    Santos, G. D. C.
    Gebbia, V.
    Perrone, F.
    Butts, C.
    Ciardiello, F.
    Feld, R.
    Gridelli, C.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S59 - S59
  • [6] GEFITINIB, ERLOTINIB AND CHEMOTHERAPY AS SECOND-LINE TREATMENT FOR PATIENT WITH ADVANCED NON-SMALL LUNG CANCER (NSCLC)
    Yang, M.
    Tan, E. C.
    Chen, Y.
    VALUE IN HEALTH, 2016, 19 (07) : A885 - A885
  • [7] Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
    Auclin, Edouard
    Benitez-Montanez, Jose
    Tagliamento, Marco
    Parisi, Francesca
    Gorria, Teresa
    Garcia-Campelo, Rosario
    Dempsey, Naomi
    Pinato, David J.
    Reyes, Roxana
    Albarran-Artahona, Victor
    Dall'Olio, Filippo
    Soldato, Davide
    Hendriks, Lizza
    Nana, Frank Aboubakar
    Tonneau, Marion
    Lopez-Castro, Rafael
    Nadal, Ernest
    Kazandjian, Suzanne
    Muanza, Thierry
    Blanc-Durand, Felix
    Fabre, Elizabeth
    Castro, Natalia
    Arasanz, Hugo
    Rochand, Adrien
    Besse, Benjamin
    Routy, Bertrand
    Mezquita, Laura
    LUNG CANCER, 2023, 178 : 116 - 122
  • [8] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
  • [9] Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Brown, T.
    Boland, A.
    Bagust, A.
    Oyee, J.
    Hockenhull, J.
    Dundar, Y.
    Dickson, R.
    Ramani, V. S.
    Proudlove, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 71 - 79
  • [10] Second-line treatment of advanced non-small cell lung cancer
    Gridelli, Cesare
    Ardizzoni, Andrea
    Ciardiello, Fortunato
    Hanna, Nasser
    Heymach, John V.
    Perrone, Francesco
    Rosell, Rafael
    Shepherd, Frances A.
    Thatcher, Nick
    Vansteenkiste, Johan
    De Petris, Luigi
    Di Maio, Massimo
    De Marinis, Filippo
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 430 - 440
12345